NEWS
Aidoc and Integral Diagnostics ( IDX ) expand AI partnership in Australia and New Zealand
platform designed to notify radiologists of lung nodules and measure them accurately , enabling earlier and appropriate intervention for lung cancer .
Aidoc , a global pioneer in clinical AI solutions , has expanded its partnership with Integral Diagnostics ( IDX ), the leading provider of AI-driven medical imaging services , across Australia and New Zealand .
This enhanced collaboration , which started four years ago , leverages Aidocs aiOS platform to alert radiologists and care teams to suspected and unsuspected critical findings in medical images .
Since 2019 , Aidoc has processed over 600,000 cases across IDX ’ s entire network – including its partner facilities and hospitals .
Looking ahead , significant advancements are on the horizon . Starting July 2025 , the Australian Government will fund the National Lung Cancer Screening Programme ( NLCSP ), a crucial step in early detection of lung cancer . IDX is currently trialling a new algorithm within Aidoc ’ s aiOS
“ Aidoc ’ s AI has significantly improved patient care and service . We ’ re keen to test and use their Chest CT AI algorithms to automate our reviews in the National Lung Cancer Screening Programme to enable us to detect disease earlier , more accurately and more efferently ,” said Dr . Ian Kadish , CEO and Managing Director at Integral Diagnostics .
Rotem Geslevich , Senior Director of Business Development , Aidoc , said : “ Our partnership with Integral Diagnostics underscores our commitment to driving better health outcomes . As the Lung Cancer Screening initiative approaches , we are excited to play a pivotal role in saving lives .”
Prenetics announces Tencent ’ s US $ 30m Investment in Insighta
Prenetics has announced that Tencent has made a strategic US $ 30 million investment in Insighta – a Hong Kong-based early cancer detection company . combined with our proprietary FRAGMA technology , positions us to make significant strides in improving early cancer diagnosis , which can greatly enhance patient outcomes worldwide .”
This investment values Insighta at US $ 200 million and underscores Tencent ’ s endeavor to advancing AI-powered innovations in healthcare .
Insighta ’ s early cancer detection platform is powered by its proprietary FRAGMA technology , a cutting-edge system designed to detect DNA methylation aberrations in cell-free DNA ( cfDNA ) in bodily fluids such as blood .
Insighta has commenced clinical trials in mainland China , focusing initially on liver cancer , and will soon expand to include lung cancer detection . Insighta is also actively developing tests for additional cancer types , and plans on updating as appropriate .
“ Tencent sees tremendous potential in Insighta ’ s FRAGMA-powered approach to early cancer detection ,” said Alexander Ng , President of Tencent Healthcare . “ We look forward to deepening our partnership with Insighta through various dimensions .”
Danny Yeung , CEO , Prenetics , said : “ This investment marks another significant step for Insighta as it continues its mission to transform cancer detection .”
With US $ 80 million in cash reserves , Insighta is well-capitalized to fund these trials and expedite the commercialization of its revolutionary cancer detection technology in the next few years .
“ We are excited to welcome Tencent as a strategic investor ,” said Professor Allen Chan , Co-founder , Insighta . “ Their expertise in AI ,
www . intelligentcio . com INTELLIGENTCIO APAC 9